EUCTR2017-004522-14-IT进行中（未招募）1 期
A phase II trial of the FGFR inhibitor INCB054828 in patients with advanced esophageal-gastric junction (EGJ)/Gastric cancer Trastuzumab Resistant: the FiGhTeR trial - FiGhTeR Study
Centro Ricerche Cliniche di Verona0 个研究点目标入组 18 人开始时间: 2019年1月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed advanced or metastatic adenocarcinoma of the stomach and the gastroesophageal junction.
- •Disease progression within 3 months of the last dose of first-line trastuzumab containing therapy.
- •Patients must have performed a fresh biopsy (at least 8-10 slides with >20% tumor content) at the baseline of study enrollment.
- •At least one measurable and evaluable disease site based on response evaluation criteria in solid tumors (RECIST v1.1).
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.
- •Age =18, no age upper limit unless patient would be unable to tolerate chemotherapy.
- •An expected survival of more than 3 months.
- •Duration from the last therapy is more than 4 weeks for other cytotoxic agents, operation or radiotherapy.
- •Major organ function has to meet the following criteria
- •oHemoglobin (Hb)>8 g/dL
- •oPLT >75 X 109/L
- •oANC >1.5 X 109/L
- •Absence of pregnacy or breastfeeding.
- •Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.
- •Patients must be accessible to follow-up and management in the treatment center.
- •Patient has to voluntarily join the study and sign the Informed Consent Form for the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjuntivitis etc, confirmed by ophthalmologic examination.
- •Any active malignancies except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix.
- •Poor-controlled arterial hypertension (sistolic blood pressure >140 mmHg and diastolic blood pressure >90 mmHg) despite standard medical management.
- •Serious cardiovascular disease: II level myocardial ischemia or myocardial infarction, arrhytmia (including QT interval prolongation, for man > 450ms, for woman > 470 ms); III-IV level cardiac function insufficiency, or echocardiography showed that left ventricular ejection fraction (LVEF) < 50%.
- •Positive urinary protein (urine protein detection of 2 or more, or 24 hour urine protein >1.0 g).
- •Total bilirubin = 1.5 × upper limit of normal (ULN; = 2.5 × ULN if Gilbert syndrome or metastatic disease involving liver).
- •AST and ALT > 2.5 × ULN (AST and ALT > 5 × ULN in the presence of liver metastases).
- •Creatinine clearance = 30 mL/min based on Cockroft-Gault
- •Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction).
- •Serum phosphate > institutional ULN.
- •Serum calcium outside of the institutional normal range or serum albumin-corrected calcium outside of the institutional normal range when serum albumin is outside of the institutional normal range.
- •History of calcium/phosphate homeostasis disorder.
- •History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification.
- •Current evidence of significant corneal disorder/keratopathy or retinal disorder, confirmed by ophthalmologic examination.
- •Factors of high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months; unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by Pis based on gastric endoscopy result.
- •Abnormal Coagulation (INR >1.5 APTT >1.5 UNL), with tendency of bleed.
研究者
相似试验
已完成
2 期
BRF113928: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer10029107non-small cell lung cancerlung cancerNL-OMON47910ovartis20
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
进行中（未招募）
1 期
Ensayo clínico y farmacocinético de fase II de infusión de 30 minutos de PM02734(Irvalec®) cada tres semanas en pacientes con cáncer no microcítico de pulmón(CNMP) epidermoide previamente tratado con al menos una línea de quimioterapiacon platinoCáncer no microcítico de pulmón (CNMP) epidermoideMedDRA version: 9.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentEUCTR2008-004908-31-ESPharma Mar S.A.20
终止
1 期
A Phase 1/2 study to determine the effect of Doxorubicin loaded EnGeneIC Delivery Vehicles on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma MultiformeCancer - BrainACTRN12613000297729EnGeneIC Ltd46
进行中（未招募）
1 期
Comparison of chemotherapy with radiochemotherapy as treatment of patients with locally advanced, primarily inoperable pancreatic carcinomalocally advanced, primarily inoperable pancreatic carcinomaEUCTR2012-001850-24-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)112